window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 21, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

phase 3 trial

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Sagimet prepares Phase 3 acne trial for first US patients

    Sagimet Biosciences is preparing to begin screening patients for its [...]

    August 27, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Grifols completes Phase 3 SPARTA study of Prolastin-C in alpha-1 emphysema

    Grifols has completed patient follow-up in its Phase 3 SPARTA [...]

    August 11, 2026
  • Biotech & Pharma Business,Central Nervous System

    Alto Neuroscience raises $100M to expand Phase 3 treatment-resistant depression programme

    Alto Neuroscience has raised $100 million through an underwritten registered [...]

    July 15, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Erasca reports encouraging Phase 1 data for ERAS-0015 and outlines Phase 3 cancer trials

    Erasca has reported updated preliminary Phase 1 data for its [...]

    July 14, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Compass reports second positive Phase 3 trial of psilocybin therapy for treatment-resistant depression

    Compass Pathways has reported positive six-month results from its second [...]

    July 8, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    FDA backs Telix Phase 3 ProstACT trial expansion into US

    Telix Pharmaceuticals has received FDA agreement on the protocol and [...]

    July 3, 2026
  • Advanced Therapies,Clinical & Regulatory,Genomics and sequencing,Therapeutic Areas

    Atsena advances gene therapy ATSN-201 into Phase 3 trial for inherited blindness

    Atsena Therapeutics has dosed the first patient in the Phase [...]

    June 22, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    AstraZeneca’s Imfinzi recommended by NICE for resectable gastric and gastro-oesophageal junction cancer

    AstraZeneca’s Imfinzi (durvalumab) has been recommended by NICE for use [...]

    May 14, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Intellia reports first positive Phase 3 in vivo CRISPR data in hereditary angioedema

    Intellia Therapeutics has reported positive Phase 3 results for lonvoguran [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Efzimfotase alfa shows mixed Phase 3 results in hypophosphatasia across pediatric and adult patients

    Efzimfotase alfa has shown positive Phase 3 results in children [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Calibre secures CQC registration for nationwide AI health service
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Digital & Data, Pharmaceuticals and therapeutics, Research & Development
  • Cyllene gene therapy for bladder disorder gains FDA RMAT designation
    Categories: Drug Discovery & Development
  • Passive cough monitoring linked to worsening asthma symptoms
    Categories: Digital & Data, Drug Discovery & Development, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top